The findings regarding the association between statins use and breast cancer are inconsistent. Given the widely and long-term use of statins as first choice drug for dyslipidemia, we conducted this meta-analysis for better understanding the associations between statins use and the risk and prognosis of breast cancer. Articles regarding effect of statins use on risk, prognosis of breast cancer and published before January 2021 were searched in the following databases: Web of Science, PubMed, EMBASE, Medline and Google Scholar. Odds ratios (ORs)/relative risks (RRs) or hazard ratios (HRs) and their 95% confidence intervals (CIs) were computed to generate a pooled effect size and 95% CI. The meta-analysis showed no significant association between statins use and risk of breast cancer (OR/RR = 1.02; 95% CI, 0.97-1.08; I2 = 76.1%; P < 0.001). The meta-analysis showed that statins use was associated with lower breast cancer recurrence, all-cause mortality and disease-specific mortality (breast cancer recurrence: HR = 0.75; 95% CI, 0.67-0.84; I2 = 31.7%; P = 0.154; all-cause mortality: HR = 0.82; 95% CI, 0.77-0.89; I2 = 67.5%; P < 0.001; and disease-specific mortality: HR = 0.82; 95% CI, 0.72-0.93; I2 = 83.6%; P < 0.001). Overall, in this report we demonstrated that the use of statins can improve the prognosis of breast cancer patients including lower risks of breast cancer recurrence, all-cause and cancer-specific mortality, though statins therapy may not have an impact on reducing the risk of breast cancer.

中文翻译：

---

他汀类药物的使用对乳腺癌风险和预后的影响：荟萃分析。

关于他汀类药物的使用与乳腺癌之间的关联的研究结果并不一致。鉴于他汀类药物作为治疗血脂异常的首选药物被广泛且长期使用，我们进行了这项荟萃分析，以更好地了解他汀类药物的使用与乳腺癌风险和预后之间的关联。在以下数据库中检索了 2021 年 1 月之前发表的有关他汀类药物使用对乳腺癌风险和预后影响的文章：Web of Science、PubMed、EMBASE、Medline 和 Google Scholar。计算优势比 (OR)/相对风险 (RR) 或风险比 (HR) 及其 95% 置信区间 (CI)，以生成汇总效应大小和 95% CI。荟萃分析显示他汀类药物的使用与乳腺癌风险之间没有显着关联（OR/RR = 1.02；95% CI，0.97-1.08；I2 = 76.1%；P < 0.001）。荟萃分析显示，他汀类药物的使用与较低的乳腺癌复发率、全因死亡率和疾病特异性死亡率相关（乳腺癌复发率：HR = 0.75；95% CI，0.67-0.84；I2 = 31.7%；P = 0.154 ；全因死亡率：HR = 0.82；95% CI，0.77-0.89；I2 = 67.5%；P < 0.001；疾病特异性死亡率：HR = 0.82；95% CI，0.72-0.93；I2 = 83.6%； P < 0.001）。总体而言，在本报告中，我们证明使用他汀类药物可以改善乳腺癌患者的预后，包括降低乳腺癌复发风险、全因死亡率和癌症特异性死亡率，尽管他汀类药物治疗可能不会对降低乳腺癌风险产生影响。乳腺癌。